









2025 ROUND TABLE



Allen Institute



Aaron CoeManaging Director, Innovation Portfolio
aaron.coe@alleninstitute.org

Aaron Coe joined the Allen Institute in 2025. As Managing Director for the Innovation Portfolio, he is responsible for cultivating relationships with scientists at the Institute across the spectrum of bioscience and technology. He is also focused on building and maintaining relationships outside the Institute that facilitate broadening our impact. This effort includes engaging investors, corporate strategic partners, and research institutions of all varieties. Aaron's experience stems from a career at the earliest stages of company formation. Aaron has held roles in operations, finance, and business development for venture-backed companies as Calistoga Pharmaceuticals. such EpiThany, BioIntervene, and Icosavax. Aaron was instrumental in Calistoga Pharmaceutical's sale to Gilead, whose efforts led to the approval of Zydelig, the world's first isoformselective PI3Kinase inhibitor.

Aaron has a degree in Linguistics and Spanish Literature from UC Santa Barbara, and an MBA from the University of Washington's Foster School of Business. Having been an exchange student in Spain and Catalonia, Aaron speaks Spanish and Catalan. He has an affinity for acquiring languages, especially the domestically accessible ones spoken right here among the various scientific units at the Allen Institute.



Debbie RynhoudExecutive Assistant
Debbie.Rynhoud@alleninstitute.org

Debbie Rynhoud is the Executive Assistant supporting Arden Yang, Vice President of Innovation. Debbie has had a varied career supporting the CEO and Board of Directors of a public aerospace company for 20 years, worked for Amazon Robotics, REI Co-op, and most recently Open Window School. She feels honored to support the important work being done at the Allen Institute, making the world a better place for all life through science.

Debbie has explored many interests from flying a Cessna 172, to writing for film, life coaching, hiking the beautiful PNW trails, collecting cookbooks and cooking with friends. What brings her the most joy is creating community at work and at home where nobody goes hungry on her watch.

Scott SmithGeneral Council
scott.smith@alleninstitute.org



Myra Wang Imanaka, PhD
Associate Director, IP Portfolio and Innovation Management
myra, imanaka@alleninstitute.org

Myra Wang joined the Allen Institute in 2019 and is responsible for managing and disseminating the Allen Institute's intellectual property in furtherance of the Institute's mission and impact. She works cross-functionally with all teams in all stages of technology management including assessment of new innovations, intellectual property rights, patent management and strategy, and licensing. She has experience in patent strategy, in-and-out licensing, and commercialization in both the research institution and life sciences company settings.

Prior to joining the Allen Institute, she did similar technology management work in the Office of Business Development and Strategy at Fred Hutch and directed intellectual property strategy at a Washington life sciences company. Myra studied at the University of Washington where she received a B.S. in biochemistry and a Ph.D. in Pathology, studying molecular regulatory mechanisms in aging and cancer.

Allen Institute



Angela YangProgram Manager, Innovation
<u>angela.yang@alleninstitute.org</u>

Angela Yang joined the Office of Science and Innovation at the Allen Institute in 2024. In her role as program manager, she is responsible for facilitating innovation ventures that build on the impact of the research at the Institute.

Yang has experience in biotech, global health, and U.S. healthcare. Prior to joining the Allen Institute, Yang worked as a consultant in Washington, D.C. advising federal healthcare clients on strategy and leading teams on business development and process improvement. Originally from Ann Arbor, Michigan, Yang received a B.S. in Neuroscience from the University of Michigan and an M.B.A. from the University of Washington Foster School of Business.




Arden Yang
Vice President, Innovation
arden.vang@alleninstitute.org

Arden Yang joined the Allen Institute in 2022. As Vice President for Innovation, he leads partnering, strategic alliance management and incubator development as part of the institute's efforts to maximize the impact of the discoveries and inventions of its scientists and engineers.

Arden's experience includes leading strategic planning, program management and technical operations at immune medicine pioneer Adaptive Biotechnologies, global biopharmaceutical firm AstraZeneca and biotechnology industry founder Genentech. At Adaptive, Arden led the building of critical planning and technical capabilities from pre-IPO through the pandemic. At AstraZeneca in global roles of increasing responsibility he led New Product Introductions, the Cambridge Strategic R&D Center program and Biologics Operations Strategy. At Genentech, Arden co-led a new technologies development program and strategic collaboration with the University of California at Berkeley and was a corporate strategic planning group lead.

Allen Institute



Benaroya Research Institute



Bolong Cao, PhDChief of Business Development bcao@benaroyaresearch.org

Bolong Cao, PhD, is the Director of Business Development a the Benaroya Research Institute at Virginia Mason (BRI). Dr. Cao was previously senior technology manager, licensing officer and technology manager for more than six years at the University of Washington Center for Commercialization (now CoMotion). Prior, he was technical director, Business Development for Cerep, Inc. in Redmond, Wash., and director, Technology Assessment and Licensing at Molecumetics, Ltd., Bellevue, Wash. Dr. Cao also has a strong scientific background and worked as a senior scientist and manager for more than seven years. He has a master's degree in business administration and holds a doctorate in chemistry/structural biology from the University of Washington.

Dr. Cao is the first Director of Business Development for BRI, a new position created to develop and implement an intellectual property management and technology commercialization strategy for the BRI portfolio of intellectual property. This includes evaluating BRI inventions for potential patents and commercialization, negotiating technology transfer and license agreements, and providing support for scientists' entrepreneurial activities such as starting companies.




Laurie SheahanBusiness Development Associate
<u>Isheahan@benaroyaresearch.org</u>

Laurie Sheahan has been in Business Development at BRI for five years. She is responsible for supporting faculty in ongoing compliance related to active agreements, coordination of patent prosecution activities, and database management.

Prior to joining Benaroya, Laurie worked in various industries, from biotech to manufacturing and SAS, managing finance and operations for small companies, and start-ups.

Office Structure/Personnel



FHCC Business
Development Team
Contact Info **Here**



Hilary Hehman Vice President, Business Development

Hilary Hehman (she, her, hers) is the Vice President of Business Development at Fred Hutch, where she creates and executes strategies aimed at growing the institutional portfolio of strategic partnerships that connect Hutch researchers with commercial partners to achieve the Center's mission - curing cancer. Hilary started her career as a bench scientist working in the Developmental Chemotherapeutics and Experimental Immunology Divisions at the National Cancer Institute before transitioning to study both business and law. Hilary is able utilize her understanding of cancer, intellectual property, and business to create collaborations with industry and venture capital funders that accelerate translation of academic science to the clinic and into the commercial market.

Hilary previously held a similar role at Cincinnati Children's Hospital Medical Center. She was also formerly a Senior Policy Analyst at the Judicial Council of California where she applied her scientific background to empirical legal research that generated hard data to evaluate statewide judicial policy initiatives.

Hilary was recently named Vice Chair of the Seattle Metropolitan Chamber of Commerce in September 2023, after having served for three years.

Hilary holds a B.S. in Microbiology from Miami University of Ohio, an M.S. in Biochemistry and Entrepreneurial Biotechnology from Georgetown University, and a J.D. from the University of California-Hastings College of the Law.



Patrick Shel byDirector of Technology Management



Gunner Johnston, PhD Sr. Technology Manager



Ziyan Zhang Technology Manager

Patrick Shelby started his professional career in the aerospace industry. After finishing graduate school and a postdoc position, Patrick was a co-founder of a diagnostic startup company. Patrick managed the New Ventures group at UW C4C and CoMotion before transitioning to Fred Hutchinson Cancer Center, where he is currently the Director of Technology Management. Patrick holds a PhD degree in Chemistry. Outside of work, he enjoy time with family, running, biking, and music.

Gunner Johnston graduated with his PhD in Immunology and Infectious Diseases from Cornell University in 2019. He caught the TTO bug as an intern at Cornell's Center for Technology Licensing and joined Fred Hutch's office of Business Development shortly after graduating. He started as the Technology Associate, responsible for managing Fred Hutch's non- financial agreements but later transitioned into IP management and licensing. As the Sr. Technology Manager, Gunner has co-led negotiations for several large licensing and Newco deals as well as supported training and mentorship of new members in the technology management team.

Ziyan Zhang joined the Business Development Office at Fred Hutchinson Cancer Center in 2021. As a Technology Manger, she is responsible for disclosure assessment, intellectual property protection and management of financial agreements. Her portfolio includes cell and gene therapy, vaccine, diagnostics, software, novel drug targets and research tools. Prior to joining Fred Hutch, Ziyan co-founded Branchly Innovation, a global platform for technology commercialization. Ziyan received a PhD in Chemistry from Washington University in St.



Alyssa Webster Technology Manager

Alyssa Webster is a scientist by training and has been at the Fred Hutchinson Cancer Center for over five years. She initially started as a postdoctoral researcher in the Clinical Research Division prior to moving into her current Business Development role as Technology Manager over two years ago. Alyssa leverages her scientific expertise to evaluate and manage new intellectual property developed in the labs at Fred Hutch, to negotiate sponsored research and license agreements, and to support new companies spinning out of Fred Hutch.



Danielle AakerSenior Technology Associate

Danielle Aaker has been a Senior Technology Associate in Business Development at the Fred Hutchinson Cancer Center since January 2022. Her expertise includes negotiating nonfinancial agreements including consortium agreements, collaboration agreements, confidentiality disclosure agreements, material transfer agreements, and data use agreements. Prior to her role at Fred Hutch, Danielle's professional experiences include being a Specialist in Tech Services with Jubilant's Contract Manufacturing and Services team and a Research Associate at NanoString Technologies, Inc. and holds a Bachelor's degree in Cellular and Molecular Biology from Winona State University.



Rachael Ste inDirector of Business Development

Rachael Stein is the Director of Business Development at the Fred Hutchinson Cancer Center, where she leads external partnering efforts through the formation of strategic relationships with biotech, pharma, and venture capital collaborators.

Before joining Fred Hutch, Rachael was a consultant at Treadstone Healthcare, conducting market analyses for life science organizations. She also completed research at the Broad Institute of MIT and Harvard, investigating mechanisms of neurodegeneration. Rachael holds a Ph.D. in Neuroscience from the University of Washington, where she focused on gene therapies for rare monogenic diseases, and a bachelor's degree from Smith College.



Neha ParanjapeBusiness Development Manager

Neha Paranjape is a business development manager at Fred Hutchinson Cancer Center since April 2023. Prior to joining the Hutch, Neha worked as a consultant at ClearView Healthcare Partners, helping biotech and pharma companies address their strategic and business needs. Neha is a scientist by training and got her Ph.D. from Indiana University, Bloomington and did her post-doctoral work at UCSF where she created models for rare genetic diseases using stem cell and CRISPR technologies.



Guru VenkatesanBusiness Development Manager

Guru Venkatesan is a Business Development Manager at Fred Hutchinson Cancer Center, where he specializes in commercializing early-stage technologies to advance cancer treatments through external partnerships and building startups. With a Ph.D. in Biomedical Engineering and experience as a Technology Commercialization Fellow at the University of Minnesota, he combines technical expertise with business insight in his current role.

During graduate school, he founded Tech Carnivol, an annual science and engineering festival—a Bonnaroo for the nerds—with unique student- designed competitions funded by industry sponsors. This festival has attracted a few thousand students since its inception. Outside of work, he is learning to navigate fatherhood with his newborn child and is developing an IP commercialization-themed board game.



Jordan Summerside
Associate Vice President
jordan.summerside@seattlechildrens.org

Jordan Summerside is associate vice president of Innovation & New Ventures at Seattle Children's. In this role, responsibilities include oversight and strategic integration of the Intellectual Property Core (tech transfer), Office of Science-Industry Partnerships, and Therapeutics Business Development. He manages the office as a centralized resource supporting company creation, commercialization, and development initiatives, with membership on several key leadership councils and direct supervision of relevant directors. The office's primary objectives are to foster institutional innovation, strengthen sustainable venture pathways, diversify revenue streams, and decrease reliance on government funding.

Previously, Jordan served as executive director of Partnerships and Special Projects at Seattle Children's, where he led strategic planning and operational leadership for multiple clinical, research, and system initiatives. Jordan has guided clinical, research, and system strategic projects from concept to implementation, major projects including leading the operational restructuring of the Seattle Cancer Care Alliance and preparing and executing the launch of BrainChild Bio, with roles focused on advancing operational readiness for new ventures and expanding institutional capabilities to execute systemwide initiatives.



Brian Phillips, PhD
Director
Brian.Phillips@seattlechildrens.org

Brian Phillips, PhD, joined Seattle Children's in 2017 as the founding director of the Intellectual Property Core. Dr. Phillips oversees the day-to-day management of the Office of Science-Industry Partnerships & the Intellectual Property Core, leading the development of strategies for academic-industry partnerships and IP development. He also serves as an observer on the Board of Directors of Be Biopharma, Inc., (previously) GentiBio, Inc. and AdaptX, Inc., all Seattle Children's startups. Previously, Dr. Phillips was Senior Licensing Manager at Baylor College of Medicine. Dr. Phillips has a BS in biology from the University of Houston and a PhD in biomedical sciences from the University of Texas M.D. Anderson Cancer Center Graduate School of Biomedical Sciences.



Eric Althoff, PhDDirector, Business Development
eric.althoff@seattlechildrens.org



Edo Mwenda, PhD

Business Development Associate
edo.mwenda@seattlechildrens.org



Tandi Collisson, JD, MSSenior Business Development Manager Tandi.Collisson@seattlechildrens.org

Eric Althoff, PhD, is director of business development and his focus is on cellular therapy and immune-oncology technologies and clinical trials. Althoff joined Seattle Children's Therapeutics after working in business development at Arzeda, a University of Washington (UW) biotech spinout he co-founded. Althoff completed his PhD in chemistry at Columbia University and his postdoctoral fellowship in computational protein design at UW.

Edo Mwenda, PhD, is a business development associate. He assists with commercializing technologies, protecting intellectual property, and facilitating market transfer and startup formation. Previously, he worked at Viksnins Harris Padys Malen LLP performing diligence on patent portfolios and drafting patent applications in polymer chemistry, nanomaterials, and small drug molecules. He co-founded QC Medchain, a startup using blockchain for secure medicine distribution, obtaining \$250,000 in non-dilutive funding from an NSF SBIR Phase I grant. Mwenda earned a BA from Macalester College and a PhD from the University of lowa, both in chemistry.

Tandi Collisson, JD, has negotiated technology license and collaborative research deals that include codevelopment agreements with CSL Behring and agreements that laid the foundation for companies such as Be Biopharma and GentiBio. She leads negotiations of other business-related contracts to facilitate the progress of research programs and commercialization efforts. Prior to her work in technology management, she worked at two life sciences companies. Collisson has a MS from UT Southwestern Medical Center, where she studied developmental neurobiology and molecular biology. She is a registered patent attorney with the U.S. Patent and Trade Office.



Kamya Rajaram, PhD
Business Development Associate
Kamya.Rajaram@seattlechildrens.org

Kamya Rajaram, PhD, is experienced in technology management, business development, contract negotiations, licensing, and commercialization. Rajaram obtained her PhD in biological sciences from Vanderbilt University, where she studied the role of microRNAs in retina regeneration. Prior to joining Seattle Children's, she completed a postdoctoral fellowship exploring the role of the microenvironment in epithelial cancer initiation at the Fred Hutch Cancer Center.



Andrea Beeks
Senior Patent and Finance Manager
Andrea.Beeks@seattlechildrens.org

Andrea Beeks is responsible for invention intake, federal reporting, and all financial matters related to the office. She has a BS in Hospitality Management from The Ohio State University (OSU) and worked at OSU's Corporate Engagement Office as a fiscal officer, where she discovered a passion for technology transfer operations. In 2017, she became director of customer implementation for a software startup spun out of OSU that focused on providing IP management solutions for technology transfer offices. She joined OSIP in 2020.

Seattle Children's Legal Services



Colleen Ottoson, JD, MPHAssociate General Counsel
colleen.ottoson@seattlechildrens.org

Colleen Ottoson, JD, MPH, leads the team within Legal Services supporting Research & Innovation. She supports Seattle Children's with complex transactions, intellectual property licensing, and research regulatory support. Colleen is co-chair of Children's Data Partnership Governance Committee, co-manager of the Research Conflict of Interest Committee, and serves on the Collaborative Action for Research Engagement Committee.




Gregg Jackson, JD, MD
Assistant General Counsel
gregg.jackson@seattlechildrens.org

Gregg Jackson, JD, MD, supports Seattle Children's with intellectual property transactions, copyright and trademark matters, the Animal Care and Use Program, and coverage analysis for clinical research. Gregg serves on Children's Coverage Analysis Committee.




Joe Terrenzio, JD Legal Program Manager joe.terrenzio@seattlechildrens.org

Joe Terrenzio, JD, supports Seattle Children's with research data use and privacy matters, vendor contracts, software outlicensing, data registries, and import/export issues. Joe is Program Manager for Children's Data Partnership Governance Committee.



Seattle Children's Legal Services



UW CoMotion



Forest Bohrer Engineering Devices & Materials, Chemistry, Cleantech



Katrina Brede Copyright & Trademark Manager



Judy Bridges Engineering Materials, Medical Devices, Chemistry



Frieda Chan Biomaterials, Diagnostics, Research Tools, Therapeutics



Laura Dorsey Copyright, Software, Training, Oceanography, Medical Devices Healthcare IT



Roï Eisenkot Bioengineering,



Dennis Hanson Therapeutics, Novel **Protein Structures**



Adam Krynicki Digital Content & Media, Databases, Training



James Lowry MTAs, NDAs, IP Language Therapeutics, Genomics, in Unfunded Research Collaborations



Jennifer McCullar Research Tools, Agriculture, Veterinary Science




Lisa Norton Bioengineering, Imaging, Medical Devices



Shamim Naigaga Shonibare Copyright, Software, Environmental Sciences

Innovation Manager Profiles and Contact Info Here

UW CoMotion



VA Technology Transfer Program



Pattie Cullum

Patricia.Cullum@va.gov

Regional Director for:Washington, Nevada, Utah, Colorado,
Arizona, New Mexico, Michigan

VA Technology Transfer Specialist Info <u>**Here**</u> **Pattie Cullum** joined the Department of Veterans Affairs Technology Transfer Program in 2019 as a Regional Director for numerous VA medical centers across multiple states. She collaborates with remarkable VA researchers, teams, affiliate universities, and business partners to manage intellectual property at all stages of technology development. Pattie evaluates VA innovations, assesses intellectual property rights, and oversees patent management and licensing processes. She promotes the commercialization of VA inventions, ultimately benefiting both veterans and the American public.

Pattie joined the federal government in 2018 as the Chief Data Scientist for the Department of Commerce, following over twenty years in the private sector, where she focused on clinical biotechnology and pharmaceutical research. She held senior leadership roles in global clinical trials, regulatory compliance, data science, data visualization and analytics, training and organizational development, and performance management.

Pattie holds a Master of Education degree from Cambridge College in Cambridge, MA, with a research focus on "The Quality of Life of HIV and AIDS patients on Highly Active Antiretroviral Therapy." She also earned a Certificate of Advanced Studies in Technology Transfer from the Foundation for Advanced Education in the Sciences (FAES) at the National Institute of Health. The Federal Lab Consortium recognized Pattie as Technology Transfer Rookie of the Year in 2022. Pattie received the Gears of Government Award in 2020, which recognizes individuals and teams across the Federal workforce whose dedication supports exceptional delivery of crucial outcomes for the American people. Additionally, she led a Leadership Training Program that Training Magazine recognized as one of the Top 100 training programs in 2017.

Pattie is dedicated to raising awareness for military and veteran caregivers while advocating for this unique community. She was selected in 2025 as an Elizabeth Dole Foundation Fellow representing New Hampshire. Pattie's appointment is a two-year immersive leadership experience, focused on building community and offering support to military and veteran caregivers.

VA Technology Transfer Program



Rowan Wagner
Rowan.Wagner@va.gov

Field Technology Transfer Specialist (Washington, Utah, Colorado) Office of Research and Development U.S. Department of Veterans Affairs Rowan Wagner is the Veterans Health Administration Technology Transfer Specialist supporting researchers and clinicians working with Veteran Health Administration in Utah, Washington, and for VA X Labs and the VA Office of Advance Manufacturing.

Each Technology Transfer Specialist manages the following for their respective regions:

- Invention evaluation
- Obtaining intellectual property protection
- Marketing inventions
- Negotiating license agreements
- Advising on IP-related agreements and CRADAs